Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.410 -0.020 (-0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,881
Open 2.400
Bid (Size) 2.370 (1)
Ask (Size) 2.480 (1)
Prev. Close 2.430
Today's Range 2.350 - 2.430
52wk Range 1.900 - 4.300
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
From Vistagen
Via Business Wire
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
From Vistagen
Via Business Wire

Performance

YTD
-27.3%
-27.3%
1 Month
+10.6%
+10.6%
3 Month
-17.7%
-17.7%
6 Month
-6.6%
-6.6%
1 Year
-41.2%
-41.2%

More News

Read More
Earnings Scheduled For February 13, 2025
Via Benzinga
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
From Vistagen
Via Business Wire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
From Vistagen
Via Business Wire
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
From Vistagen
Via Business Wire
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
From Vistagen
Via Business Wire
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
From Vistagen
Via Business Wire
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Vistagen to Present at the Stifel 2024 Healthcare Conference
From Vistagen
Via Business Wire
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
From Vistagen
Via Business Wire
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
From Vistagen
Via Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Joint Ceremony to Ring Nasdaq Closing Bell in Honor of World Mental Health Day
Via Investor Brand Network
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
From Vistagen
Via Business Wire
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
Via Investor Brand Network
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025
Via InvestorPlace
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call
Via Investor Brand Network
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
From Vistagen
Via Business Wire
3 Stocks Under $15 That Could Make You a Millionaire
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 2.410
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 05/23/25 04:00 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 22.56M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback